Viatris ROE 2010-2024 | VTRS

Current and historical return on equity (ROE) values for Viatris (VTRS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Viatris ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-12-31 $-0.63B $18.64B -3.25%
2024-09-30 $-0.88B $19.79B -4.43%
2024-06-30 $-0.65B $19.52B -3.20%
2024-03-31 $-0.06B $20.01B -0.27%
2023-12-31 $0.05B $20.47B 0.26%
2023-09-30 $1.83B $20.87B 8.75%
2023-06-30 $1.85B $20.84B 9.04%
2023-03-31 $1.90B $20.93B 9.40%
2022-12-31 $2.08B $21.07B 10.32%
2022-09-30 $0.80B $19.18B 4.02%
2022-06-30 $0.76B $19.81B 3.72%
2022-03-31 $0.17B $20.45B 0.81%
2021-12-31 $-1.27B $20.49B -6.02%
2021-09-30 $-1.92B $21.14B -8.86%
2021-06-30 $-2.05B $21.21B -10.48%
2021-03-31 $-1.73B $21.42B -10.07%
2020-12-31 $-0.67B $22.95B -4.58%
2020-09-30 $0.27B $12.55B 2.25%
2020-06-30 $0.27B $11.75B 2.34%
2020-03-31 $0.06B $11.26B 0.54%
2019-12-31 $0.02B $11.88B 0.14%
2019-09-30 $0.05B $11.46B 0.40%
2019-06-30 $0.03B $11.90B 0.28%
2019-03-31 $0.24B $11.89B 1.99%
2018-12-31 $0.35B $12.17B 2.85%
2018-09-30 $0.55B $12.07B 4.30%
2018-06-30 $0.46B $12.21B 3.52%
2018-03-31 $0.72B $13.18B 5.44%
2017-12-31 $0.70B $13.31B 5.44%
2017-09-30 $0.87B $13.29B 7.11%
2017-06-30 $0.66B $12.83B 5.57%
2017-03-31 $0.53B $11.66B 4.74%
2016-12-31 $0.48B $11.12B 4.41%
2016-09-30 $0.26B $11.83B 2.44%
2016-06-30 $0.81B $10.33B 8.02%
2016-03-31 $0.81B $10.28B 8.18%
2015-12-31 $0.85B $9.77B 8.88%
2015-09-30 $0.84B $9.82B 10.62%
2015-06-30 $0.91B $9.57B 14.41%
2015-03-31 $0.87B $9.09B 18.19%
2014-12-31 $0.93B $3.28B 28.09%
2014-09-30 $0.92B $3.41B 28.50%
2014-06-30 $0.58B $3.35B 18.21%
2014-03-31 $0.63B $3.19B 20.54%
2013-12-31 $0.62B $2.96B 20.76%
2013-09-30 $0.61B $3.23B 19.52%
2013-06-30 $0.66B $2.95B 20.54%
2013-03-31 $0.62B $2.89B 18.95%
2012-12-31 $0.64B $3.36B 18.37%
2012-09-30 $0.61B $3.62B 17.24%
2012-06-30 $0.55B $3.20B 15.85%
2012-03-31 $0.56B $3.78B 15.31%
2011-12-31 $0.54B $3.51B 14.49%
2011-09-30 $0.41B $3.49B 11.00%
2011-06-30 $0.36B $3.88B 9.65%
2011-03-31 $0.27B $3.92B 7.57%
2010-12-31 $0.22B $3.62B 6.70%
2010-09-30 $0.22B $3.54B 6.98%
2010-06-30 $0.08B $2.98B 2.46%
2010-03-31 $0.08B $3.18B 2.70%
2009-12-31 $0.09B $3.15B 3.16%
Sector Industry Market Cap Revenue
Medical Medical Services $13.595B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $150.904B 28.19
Elevance Health (ELV) United States $87.590B 11.69
CVS Health (CVS) United States $79.455B 11.63
Cencora (COR) United States $47.362B 17.19
DiDi Global (DIDIY) China $23.670B 0.00
Natera (NTRA) United States $20.908B 0.00
ICON (ICLR) Ireland $16.429B 14.61
Revvity (RVTY) United States $13.985B 23.45
BioMerieux (BMXMF) France $13.758B 0.00
Doximity (DOCS) United States $13.537B 70.40
Solventum (SOLV) United States $13.178B 0.00
Avantor (AVTR) United States $11.895B 17.47
CochLear (CHEOY) Australia $11.072B 0.00
Medpace Holdings (MEDP) United States $10.491B 27.26
EUROFINS SCIENT (ERFSF) Luxembourg $9.952B 0.00
HealthEquity (HQY) United States $9.484B 47.58
Charles River Laboratories (CRL) United States $8.719B 16.52
Sonic Healthcare (SKHHY) Australia $8.501B 0.00
Amplifon S.p.A (AMFPF) Italy $6.224B 31.72
Bausch + Lomb (BLCO) Canada $5.573B 25.50
Organon (OGN) United States $3.884B 3.96
Sotera Health (SHC) United States $3.814B 20.40
BrightSpring Health Services (BTSG) United States $3.382B 71.93
Surgery Partners (SGRY) United States $3.198B 36.46
Concentras Parent (CON) United States $2.951B 0.00
Alignment Healthcare (ALHC) United States $2.613B 0.00
GeneDx Holdings (WGS) United States $2.610B 316.67
Ardent Health Partners (ARDT) United States $2.014B 0.00
PACS (PACS) United States $1.980B 0.00
Progyny (PGNY) United States $1.961B 39.71
Teladoc Health (TDOC) United States $1.961B 0.00
GoodRx Holdings (GDRX) United States $1.845B 48.40
Premier (PINC) United States $1.690B 10.82
Agilon Health (AGL) United States $1.500B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.409B 0.00
Pediatrix Medical (MD) United States $1.346B 11.28
CareDx (CDNA) United States $1.146B 0.00
AMN Healthcare Services Inc (AMN) United States $1.026B 8.12
Establishment Labs Holdings (ESTA) $0.986B 0.00
Embecta (EMBC) United States $0.798B 5.47
Auna S.A (AUNA) Luxembourg $0.598B 0.00
SBC Medicals (SBC) United States $0.484B 0.00
MultiPlan (MPLN) United States $0.472B 0.00
Sonida Senior Living (SNDA) United States $0.472B 0.00
DocGo (DCGO) United States $0.453B 17.08
InnovAge Holding (INNV) United States $0.449B 0.00
Enhabit (EHAB) United States $0.406B 35.09
QDM (QDMI) Hong Kong, SAR China $0.335B 8.78
Nutex Health (NUTX) United States $0.314B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.253B 0.00
LifeMD (LFMD) United States $0.248B 0.00
Beauty Health (SKIN) United States $0.194B 0.00
Performant Healthcare (PHLT) United States $0.193B 0.00
Sera Prognostics (SERA) United States $0.140B 0.00
Biodesix (BDSX) United States $0.122B 0.00
So-Young (SY) China $0.116B 19.63
Ascend Wellness Holdings (AAWH) United States $0.086B 0.00
IceCure Medical (ICCM) Israel $0.078B 0.00
ModivCare (MODV) United States $0.071B 3.85
Oncology Institute (TOI) United States $0.064B 0.00
NeueHealth (NEUE) United States $0.061B 1.61
OncoCyte (OCX) United States $0.046B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.035B 0.00
Co-Diagnostics (CODX) United States $0.020B 0.00
Intelligent Bio Solutions (INBS) United States $0.015B 0.00
Pheton Holdings (PTHL) China $0.014B 0.00
KindlyMD (KDLY) United States $0.013B 0.00
SeaStar Medical Holding (ICU) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
XWELL (XWEL) United States $0.006B 0.00
Aclarion (ACON) United States $0.002B 0.00
ISpecimen (ISPC) United States $0.002B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00